Supplementary Figures 1 - 5 from Bispecific Antibody to ErbB2 Overcomes Trastuzumab Resistance through Comprehensive Blockade of ErbB2 Heterodimerization

PDF file - 362K, Competitive binding assay (S1); TPL inhibits ErbB2 signaling in breast cancer cell lines (S2); ErbB2 knockdown inhibits ErbB2 signaling and results in growth inhibition in the MDA-MB-231 cell line (S3); TPL inhibited MDA-MB-231 breast cancer cell growth in a dose-dependent manner both in vitro and in vivo (S4); The effects of siRNA knockdown of EGFR or ErbB3 on the BT-474TraR cell line (S5).